About Interleukin-13 receptor subunit alpha-1
Interleukin-13 receptor subunit alpha-1 (IL13RA1) is a protein
from Homo sapiens identified by UniProt accession
P78552, 427 residues long.
MolForge cross-references it against 0 known binders and
287 disease associations.
Target properties
| Protein name | Interleukin-13 receptor subunit alpha-1 |
| UniProt accession | P78552 |
| Gene | IL13RA1 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (287)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.36
- glioblastoma multiforme · score 0.30
- neurodegenerative disease · score 0.27
- complication · score 0.19
- head and neck squamous cell carcinoma · score 0.19
- endometrial cancer · score 0.18
- low grade glioma · score 0.18
- breast adenocarcinoma · score 0.18
- gastric adenocarcinoma · score 0.15
- esophageal cancer · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78552-F1 | alphafold | PREDICTED | 81.55 | — |
Amino-acid sequence (427 residues)
MEWPARLCGL WALLLCAGGG GGGGGAAPTE TQPPVTNLSV SVENLCTVIW TWNPPEGASS NCSLWYFSHF GDKQDKKIAP ETRRSIEVPL NERICLQVGS QCSTNESEKP SILVEKCISP PEGDPESAVT ELQCIWHNLS YMKCSWLPGR NTSPDTNYTL YYWHRSLEKI HQCENIFREG QYFGCSFDLT KVKDSSFEQH SVQIMVKDNA GKIKPSFNIV PLTSRVKPDP PHIKNLSFHN DDLYVQWENP QNFISRCLFY EVEVNNSQTE THNVFYVQEA KCENPEFERN VENTSCFMVP GVLPDTLNTV RIRVKTNKLC YEDDKLWSNW SQEMSIGKKR NSTLYITMLL IVPVIVAGAI IVLLLYLKRL KIIIFPPIPD PGKIFKEMFG DQNDDTLHWK KYDIYEKQTK EETDSVVLIE NLKKASQ
Explore Interleukin-13 receptor subunit alpha-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets